{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Agent Affecting Blood or Body Fluid" in comments (approximate match)
Status:
US Approved Rx
(2014)
First approved in 2009
Class:
PROTEIN
Status:
US Approved Rx
(2008)
First approved in 2008
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2007
Class:
PROTEIN
Status:
US Approved Rx
(2007)
First approved in 2003
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
NDA211215
(2019)
Source URL:
First approved in 2000
Source:
NDA020873
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.
Status:
US Approved Rx
(2000)
Source:
BLA103909
(2000)
Source URL:
First approved in 2000
Source:
BLA103909
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
First approved in 1998
Source:
BLA103980
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103786
(1998)
Source URL:
First approved in 1996
Source:
BLA103786
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 1990
Source:
ALPHANINE SD by GRIFOLS BIOLOGICALS LLC
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
First approved in 1947
Class:
PROTEIN
